Middle East Healthcare Company vs DaVita Inc.
A head-to-head of Middle East Healthcare Company (4009) and DaVita Inc. (DVA) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 4009 | DVA |
|---|---|---|
| Market Cap | 3.13B SAR | $15.21B |
| P/E (TTM) | 9.71 | 21.98 |
| Forward P/E | 8.52 | 11.63 |
| P/S | 1.00 | 0.91 |
| P/B | 1.54 | 15.64 |
| EV/EBITDA | — | 8.90 |
| Dividend Yield | 1.47% | — |
| Profit Margin | 5.34% | 5.65% |
| Gross Margin | 37.39% | 32.25% |
| Operating Margin | 12.67% | 14.74% |
| Revenue Growth (YoY) | +4.29% | +5.96% |
| FCF Yield | 9.73% | 12.00% |
| Debt / Equity | 123.07 | 1013.79 |
| Current Ratio | 1.48 | 1.42 |
Which is better: Middle East Healthcare Company or DaVita Inc.?
- ✓Larger by market cap: DaVita Inc.
- ✓Cheaper valuation (lower P/E): Middle East Healthcare Company
- ✓More profitable (net margin): DaVita Inc.
- ✓Faster revenue growth: DaVita Inc.
- ✓Higher free-cash-flow yield: DaVita Inc.
Across 11 available metrics, Middle East Healthcare Company leads 6–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Middle East Healthcare Company with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.